CTNM Stock Summary and Trading Ideas (Contineum Therapeutics | NASDAQ:CTNM)

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics trades on the NASDAQ stock market under the symbol CTNM.

As of May 8, 2024, CTNM stock price climbed to $15.39 with 94,229 million shares trading.

CTNM has a market cap of $386.76 million. This is considered a Small Cap stock.

CTNM support price is $13.99 and resistance is $15.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTNM stock will trade within this expected range on the day.